Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis

Francesconi, Glaucia; Valle, AC; Passos, Sônia Regina Lambert; Reis, Rodrigo S.; Mc, Galhardo

doi:10.1111/j.1468-3083.2009.03306.x

Cited by 54 publications

(33 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five patients from South Africa were cured with 250 mg twice daily administered for 8 to 37 weeks (mean, 18; median, 14) [40], and 12 of 16 Japanese patients were cured with 125 mg daily (although the dose was raised to 250 mg daily in two of them), administered for a range of 10 to 21 weeks [36]. Also, 86% of 45 Brazilian patients with contraindications for itraconazole treatment were cured with terbinafine, 250 mg daily [41]. Favorable responses with dosing lower than 500 mg twice daily could be explained by involvement of different Sporothrix species or strains.…”

Section: Terbinafinementioning

confidence: 97%

Sporotrichosis Treatment: Overview and Update

Bustamante

Campos

2010

Curr Fungal Infect Rep

View full text Add to dashboard Cite

Sporotrichosis, caused by several species from the genus Sporothrix, mainly affects men working in agricultural labor. It is reported mostly from endemic regions located in tropical and subtropical areas. Sporotrichosis usually affects subcutaneous tissue with no symptoms or mild symptoms, but it causes disseminated and even fatal disease if the patient is immunocompromised. Significant progress in the knowledge of etiologic agents of sporotrichosis has been achieved recently, but evaluations of treatment using welldesigned clinical trials have been neglected. This article reviews the drugs currently used to treat subcutaneous disease, describing the differences in their efficacy, and reviews recent findings about the proposed new Sporothrix species of clinical interest, as well as the role of melanin as a virulence factor in Sporothrix schenckii.

show abstract

Section: Terbinafinementioning

confidence: 97%

Sporotrichosis Treatment: Overview and Update

Bustamante

Campos

2010

Curr Fungal Infect Rep

View full text Add to dashboard Cite

show abstract

“…The three studies using terbinafine in human patients demonstrated a good efficacy for doses ranging from 250 to 1,000 mg/day (43,73,74). A study comparing 250 mg/day of terbinafine to 100 mg/day of itraconazole resulted in healing in 92.7% and 92% of patients, respectively, indicating terbinafine to be an effective and well-tolerated option for the treatment of cutaneous sporotrichosis (73).…”

Section: Treatmentmentioning

confidence: 99%

Sporothrix schenckii and Sporotrichosis

Barros

Paes²,

Schubach³

2011

Clin Microbiol Rev

520

677

View full text Add to dashboard Cite

SUMMARY Sporotrichosis, which is caused by the dimorphic fungus Sporothrix schenckii , is currently distributed throughout the world, especially in tropical and subtropical zones. Infection generally occurs by traumatic inoculation of soil, plants, and organic matter contaminated with the fungus. Certain leisure and occupational activities, such as floriculture, agriculture, mining, and wood exploitation, are traditionally associated with the mycosis. Zoonotic transmission has been described in isolated cases or in small outbreaks. Since the end of the 1990s there has been an epidemic of sporotrichosis associated with transmission by cats in Rio de Janeiro, Brazil. More than 2,000 human cases and 3,000 animal cases have been reported. In humans, the lesions are usually restricted to the skin, subcutaneous cellular tissue, and adjacent lymphatic vessels. In cats, the disease can evolve with severe clinical manifestations and frequent systemic involvement. The gold standard for sporotrichosis diagnosis is culture. However, serological, histopathological, and molecular approaches have been recently adopted as auxiliary tools for the diagnosis of this mycotic infection. The first-choice treatment for both humans and cats is itraconazole.

show abstract

“…In a comparative study, Song et al [59] demonstrated similar efficacy and safety of itraconazole pulse regimen (200 mg bd for 1 week with a 3 week break) to the continuous (100 mg bd) regimen. Terbinafine 250 mg daily is equally efficacious as itraconazole 100 mg daily for cutaneous sporotrichosis [60] and has also been shown to be a well tolerated alternative in cases when itraconazole is contraindicated or resulted in significant drug interactions [61]. Ketoconazole is not recommended because of its inferior efficacy and significant adverse effects [54].…”

Section: Sporotrichosismentioning

confidence: 98%